Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Prospector Partners LLC

Prospector Partners LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 160,491 shares of the medical equipment provider's stock after buying an additional 27,786 shares during the quarter. Prospector Partners LLC owned about 0.07% of Hologic worth $11,570,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in Hologic in the 4th quarter valued at about $133,414,000. Boston Partners lifted its stake in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Hologic during the 4th quarter valued at approximately $27,007,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Hologic by 27.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,687,347 shares of the medical equipment provider's stock worth $121,641,000 after purchasing an additional 361,539 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent analyst reports. Evercore ISI decreased their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research report on Thursday, February 6th. Wolfe Research assumed coverage on shares of Hologic in a report on Friday, December 13th. They set a "peer perform" rating for the company. Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Finally, Argus lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $84.62.

Remove Ads

Hologic Stock Performance

HOLX stock traded up $0.79 during mid-day trading on Friday, reaching $57.95. The company had a trading volume of 1,581,672 shares, compared to its average volume of 1,899,137. Hologic, Inc. has a one year low of $56.31 and a one year high of $84.67. The stock has a market capitalization of $13.00 billion, a P/E ratio of 18.19, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock's 50-day simple moving average is $62.74 and its two-hundred day simple moving average is $71.71.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.